Home/Browse by collection/Clinical/Translational Cancer Immunotherapy

Clinical/Translational Cancer Immunotherapy

Section Edited by Jason J. Luke, MD, FACP and Douglas G. McNeel, MD, PhD Clinical trials: prospective studies including first-in-man clinical trials, phase II/III clinical studies, and immune monitoring investigations. Small, single institution-based retrospective reports are discouraged. Preclinical studies: studies that lead to mechanistic understanding or novel development of agents and combination therapies directly relevant to human immunotherapy.

Showing results 1 - 10 of 100

Sorted by most recent

Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL
Ekaterina Mikhailova, Alexander Popov, Julia Roumiantseva, Oleg Budanov, Svetlana Lagoyko, Liudmila Zharikova, Natalia Miakova, Dmitry Litvinov, Lili Khachatryan, Alexey Pshonkin, Natalia Ponomareva, Elmira Boichenko, Svetlana Varfolomeeva, Julia Dinikina, Galina NovichkovaSee the full list of authors

6 June 2024